Thus, crystal-induced TNF-α release and the subsequent TNFR1-triggered activation of RIPK1–RIPK3–MLKL-executed tubular cell necroptosis represent therapeutic targets in CN. Here, MLKL is linked to cyclic hematopoiesis.